Back

prof. dr. M. (Miriam) Koopman

prof. dr. M. (Miriam) Koopman

Full Professor

Show full profile

Research Output (219)

Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study

Koopman Miriam, Venderbosch Sabine, van Tinteren Harm, Ligtenberg Marjolijn J, Nagtegaal Iris, Van Krieken Johan H, Punt Cornelis J Jul 2009, In: European Journal of Cancer. 45 , p. 1999-2006 8 p.

A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?

Koopman Miriam, Venderbosch Sabine, Nagtegaal Iris D, van Krieken Johan H, Punt Cornelis J Jul 2009, In: European Journal of Cancer. 45 , p. 1935-49 15 p.

Pylephlebitis after a duodenal ulcer in a patient with metastasised colon carcinoma treated with chemotherapy and bevacizumab:A case report

Mannaerts L., Bleeker-Rovers C. P., Koopman M., Punt C. J A, van Herpen C. M L Feb 2009, In: Netherlands Journal of Medicine. 67 , p. 69-71 3 p.

The CAIRO and FOCUS studies:which lesson is to be learned?

Koopman Miriam, Seymour Matthew T, Punt Cornelis J A Feb 2009, In: Oncologist. 14 , p. 192-3; author reply 194-6

Deficient mismatch repair system in patients with sporadic advanced colorectal cancer

Koopman M., Kortman G. A M, Mekenkamp L., Ligtenberg M. J L, Hoogerbrugge N., Antonini N. F., Punt C. J A, Van Krieken J. H J M 27 Jan 2009, In: British Journal of Cancer. 100 , p. 266-273 8 p.

Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma

Soetekouw Patricia M M B, Koopman M., Burger David, Tjan-Heijnen Vivianne C G, De Mulder P. H M Jan 2009, In: Acta Oncologica. 48 , p. 154-156 3 p.

DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer

Postma C., Koopman M., Buffart T. E., Eijk P. P., Carvalho B., Peters G. J., Ylstra B., Van Krieken J. H., Punt C. J A, Meijer G. A. 2009, In: Annals of Oncology. 20 , p. 1048-1056 9 p.

Current status of the systemic treatment of metastatic colorectal cancer

Punt C. J A, Mekenkamp L. J M, Tol Jolien, Koopman Miriam 2009, In: EJHP Practice. 15 , p. 62-65 4 p.

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Tol J, Koopman M., Cats A., Rodenburg J., Creemers G.J., Schrama J.G., Erdkamp F.L., Vos A.H., van Groeningen C.J., Sinnige H.A., Richel D.J., Voest E.E., Dijkstra J.R., Vink Borger M.E., Antonini N.F., Mol L., van Krieken J.H.J.M, Dalesio O., Punt C.J. 2009, In: New England Journal of Medicine. 360 , p. 563-572 10 p.

GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan:A study of the Dutch Colorectal Cancer Group

Kweekel D. M., Koopman M., Antonini N. F., Van Der Straaten T., Nortier J. W R, Gelderblom H., Punt C. J A, Guchelaar H. J. 21 Oct 2008, In: British Journal of Cancer. 99 , p. 1316-1321 6 p.

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not